+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID06797999

First-in-Human Study Evaluating Safety and Antitumor Activity of ADCE-D01 in Patients with Metastatic or Unresectable Soft Tissue Sarcoma

Led by Adcendo ApS · Updated on 2026-09-11

270

Participants Needed

9

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the safety, tolerability, and effectiveness of ADCE-D01, an antibody-drug conjugate, in adults with metastatic or unresectable soft tissue sarcoma. This first-in-human study evaluates how well the treatment works by looking at tumor response and other measures such as progression-free survival and duration of response. The study is open-label and includes dose escalation to find the appropriate dose. Participants receive ADCE-D01, which combines a humanized antibody targeting uPARAP with a chemotherapy agent linked via a special connector. The treatment is given in phases, starting with dose escalation to determine the maximum tolerated dose and recommended dose for expansion. The study continues to monitor safety, drug levels in the body, and tumor activity throughout the trial. During the trial, participants undergo regular safety assessments, imaging scans to measure tumor size, blood tests to check drug concentration, and evaluations of physical condition. Researchers carefully track side effects and how long the treatment controls the disease. The study is expected to last about 18 months after enrollment completion, with ongoing monitoring of treatment effects and safety throughout this time.

CONDITIONS

Brief Title

First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma

Research Team

R

René Smrčka

M

Margaret McNaull

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here